Pfizer has reached a turning point.

Sales of Pfizer's COVID-19 products have collapsed. Thanks to heavy investment fueled by COVID-related revenue, Pfizer has a big pipeline of new potential blockbuster drugs. Cancer treatments Pfizer ...

PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.

In early March 2026, Pfizer reported past Phase 2 trial results showing its investigational trispecific antibody tilrekimig significantly improved eczema severity versus placebo in adults with ...

Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance ...

PFE stock is up 11% in 2026, but flat guidance, falling COVID sales and patent cliffs cloud its rebound story. Buy, sell or hold?

Approximately a quarter of Pfizer's revenue and net income face patent expiry risk. Click here to read why PFE stock remains a Hold.